NO20080371L - Fremgangsmate for a forutsi responsen overfor en behandling - Google Patents

Fremgangsmate for a forutsi responsen overfor en behandling

Info

Publication number: NO20080371L
Authority: NO; Norway
Prior art keywords: marker gene; response; growth factor; treatment; patient
Prior art date: 2005-08-12

Application number

NO20080371A

Other languages

English (en)

Norwegian (no)

Inventor

Joachim Moecks

Andreas Strauss

Gerhard Zugmaier

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-12

Filing date

2008-01-21

Publication date

2008-05-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35511140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080371(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-21 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2008-05-09 Publication of NO20080371L publication Critical patent/NO20080371L/no

Links

238000000034 method Methods 0.000 title abstract 3
239000003550 marker Substances 0.000 abstract 7
108090000623 proteins and genes Proteins 0.000 abstract 7
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 2
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 2
101800003838 Epidermal growth factor Proteins 0.000 abstract 2
239000004010 HER dimerization inhibitor Substances 0.000 abstract 2
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 2
101800004564 Transforming growth factor alpha Proteins 0.000 abstract 2
229940116977 epidermal growth factor Drugs 0.000 abstract 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 2
102100038778 Amphiregulin Human genes 0.000 abstract 1
108010033760 Amphiregulin Proteins 0.000 abstract 1
239000012472 biological sample Substances 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Hospice & Palliative Care (AREA)
General Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Food Science & Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)

NO20080371A 2005-08-12 2008-01-21 Fremgangsmate for a forutsi responsen overfor en behandling NO20080371L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05017663		2005-08-12
PCT/EP2006/004950 WO2007019899A2 (fr)	2005-08-12	2006-05-24	Method for predicting the response to a treatment

Publications (1)

Publication Number	Publication Date
NO20080371L true NO20080371L (no)	2008-05-09

Family

ID=35511140

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20080371A NO20080371L (no)	2005-08-12	2008-01-21	Fremgangsmate for a forutsi responsen overfor en behandling

Country Status (32)

Country	Link
US (2)	US7700299B2 (fr)
EP (2)	EP1915460B1 (fr)
JP (1)	JP2009504142A (fr)
KR (2)	KR20110074921A (fr)
CN (2)	CN101405405A (fr)
AR (1)	AR057323A1 (fr)
AT (2)	ATE493514T1 (fr)
AU (2)	AU2006281746B2 (fr)
BR (1)	BRPI0615001A2 (fr)
CA (1)	CA2616913A1 (fr)
CL (1)	CL2010000720A1 (fr)
CR (1)	CR9686A (fr)
CY (1)	CY1111612T1 (fr)
DE (1)	DE602006019265D1 (fr)
DK (1)	DK1915460T3 (fr)
EC (1)	ECSP088171A (fr)
ES (1)	ES2356066T3 (fr)
HR (1)	HRP20110171T1 (fr)
IL (1)	IL188923A0 (fr)
MA (1)	MA31549B1 (fr)
MX (1)	MX2008001926A (fr)
NO (1)	NO20080371L (fr)
NZ (1)	NZ565270A (fr)
PL (1)	PL1915460T3 (fr)
PT (1)	PT1915460E (fr)
RS (1)	RS51859B (fr)
RU (2)	RU2408735C2 (fr)
SI (1)	SI1915460T1 (fr)
TW (1)	TW200741010A (fr)
UA (1)	UA93989C2 (fr)
WO (1)	WO2007019899A2 (fr)
ZA (1)	ZA201102688B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA9811162B (en)	1997-12-12	2000-06-07	Genentech Inc	Treatment with anti-ERBB2 antibodies.
CN1447696A (zh) *	2000-05-19	2003-10-08	杰南技术公司	用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
SV2006002143A (es) *	2004-06-16	2006-01-26	Genentech Inc	Uso de un anticuerpo para el tratamiento del cancer resistente al platino
DK1771482T3 (da) *	2004-07-22	2014-10-20	Genentech Inc	HER2-antistofsammensætning
JO3000B1 (ar) *	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
ZA200704796B (en) *	2004-12-07	2008-11-26	Genentech Inc	Selecting patients for therapy with a HER inhibitor
TWI441646B (zh) *	2005-01-21	2014-06-21	Genentech Inc	帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
MY152164A (en) *	2005-02-23	2014-08-15	Genentech Inc	Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) *	2005-07-22	2007-03-09	Genentech Inc	Tratamiento combinado de los tumores que expresan el her
EP1917528B1 (fr) *	2005-08-24	2011-08-17	Bristol-Myers Squibb Company	Marqueurs biologiques et procedes permettant de determiner la receptivite aux modulateurs du recepteur du facteur de croissance epidermique (egfr)
SI2132573T1 (sl) *	2007-03-02	2014-07-31	Genentech, Inc.	Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
JP5433189B2 (ja) *	2007-09-28	2014-03-05	承一尾崎	Ｍｐｏ−ａｎｃａ関連血管炎の被験者に対する治療の効果を予測する材料を提供する方法
US10416162B2 (en) *	2007-12-20	2019-09-17	Monogram Biosciences, Inc.	Her2 diagnostic methods
NZ586544A (en) *	2007-12-26	2012-07-27	Vaccinex Inc	Anti-c35 antibody in combination with an ani-her2 antibody in cancer therapies and methods
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
PL2260111T3 (pl) *	2008-03-14	2015-11-30	Genentech Inc	Zróżnicowanie genetyczne powiązane z lekoopornością
ES2430590T3 (es)	2008-05-14	2013-11-21	Genomic Health, Inc.	Predictores de la respuesta de pacientes al tratamiento con inhibidores del receptor del EGF
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
WO2010065568A2 (fr)	2008-12-01	2010-06-10	Laboratory Corporation Of America Holdings	Procédés et dosages pour mesurer p95 et/ou p95 dans un échantillon et anticorps spécifiques de p95
KR20110120891A (ko) *	2009-01-15	2011-11-04	래버러토리 코포레이션 오브 아메리카 홀딩스	Ｈｅｒ-３의 측정에 의한 환자 반응의 결정 방법
BRPI1007048A2 (pt) *	2009-01-15	2016-02-10	Lab Corp America Holdings	método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
US9345661B2 (en) *	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es)	2009-09-11	2011-10-19	Hoffmann La Roche	Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
CN103109185A (zh) *	2010-04-18	2013-05-15	耶达研究及发展有限公司	用于治疗ErbB/ErbB配体相关疾病的分子和使用所述分子的方法
US9211263B2 (en)	2012-01-06	2015-12-15	Elcelyx Therapeutics, Inc.	Compositions and methods of treating metabolic disorders
SG10201607085WA (en) *	2011-01-07	2016-10-28	Elcelyx Therapeutics Inc	Chemosensory Receptor Ligand-Based Therapies
US11759441B2 (en)	2011-01-07	2023-09-19	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en)	2011-01-07	2024-05-07	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
EP2764364B1 (fr) *	2011-10-06	2021-08-18	Aveo Pharmaceuticals, Inc.	Prédiction de réaction de tumeur à des anticorps anti-erbb3
KR102679155B1 (ko)	2011-10-14	2024-06-28	제넨테크, 인크.	Her2 이량체화 억제제인 페르투주맙의 용도 및 이를 포함하는 제조품
AU2013207329B2 (en)	2012-01-06	2017-10-26	Anji Pharmaceuticals Inc.	Compositions and methods for treating metabolic disorders
AU2012363873B2 (en)	2012-01-06	2017-11-23	Anji Pharmaceuticals Inc.	Biguanide compositions and methods of treating metabolic disorders
RU2737727C2 (ru)	2013-04-16	2020-12-02	Дженентек, Инк.	Варианты пертузумаба и их аналитическая характеристика
CA2919477A1 (fr) *	2013-07-31	2015-02-05	Dana-Farber Cancer Institute, Inc.	Compositions et methodes de modulation de thermogenese a l'aide de molecules liees a la pth et liees au egf
EP2876442A1 (fr) *	2013-11-22	2015-05-27	Institut de Cancérologie de l'Ouest	Olfactomedine 4, neudésine et desmoplakine en tant que biomarqueurs du cancer du sein
WO2015164665A1 (fr)	2014-04-25	2015-10-29	Genentech, Inc.	Méthodes de traitement du cancer du sein précoce avec du trastuzumab-mcc-dm1 et du pertuzumab
CA2955456A1 (fr)	2014-07-17	2016-01-21	Brian J. Czerniecki	Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
HRP20241134T1 (hr)	2015-05-30	2024-11-22	F. Hoffmann-La Roche Ag	Metode liječenja her2-pozitivnog prethodno neliječenog metastatskog raka dojke
CA2992925A1 (fr) *	2015-07-17	2017-01-26	The Trustees Of The University Of Pennsylvania	Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie
WO2017087280A1 (fr)	2015-11-16	2017-05-26	Genentech, Inc.	Procédés de traitement d'un cancer positif her2
CN105403704A (zh) *	2015-12-31	2016-03-16	苏州市博纳泰科生物技术有限公司	Her-2的荧光免疫层析检测方法及试剂盒
MX2019005144A (es)	2016-11-04	2019-10-14	Genentech Inc	Tratamiento de cáncer de mama positivo para her2.
TW201827077A (zh)	2016-12-28	2018-08-01	美商建南德克公司	晚期her2表現癌症之治療
KR20200113292A (ko)	2017-01-17	2020-10-06	제넨테크, 인크.	피하 her2 항체 제형
SI3589661T1 (sl)	2017-03-02	2024-03-29	Genentech, Inc.	Adjuvansno zdravljenje her2 pozitivnega raka dojke
WO2018200505A1 (fr)	2017-04-24	2018-11-01	Genentech, Inc.	Mutations erbb2/her2 dans le domaine transmembranaire ou juxtamembranaire
EP3816285A4 (fr)	2018-05-25	2022-03-16	Bioneer Corporation	Oligonucléotide double brin spécifique du gène de l'amphiréguline et composition, pour la prévention et le traitement de maladies liées à la fibrose et de maladies respiratoires, comprenant ceux-ci
JP2023532122A (ja)	2020-06-29	2023-07-26	ジェネンテック，インコーポレイテッド	ペルツズマブにトラスツズマブを加えた固定用量配合剤
EP4568994A1 (fr) *	2022-08-09	2025-06-18	Heligenics, Inc.	Procédé d'évaluation de la pertinence clinique d'une variance génétique

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5401638A (en)	1986-06-04	1995-03-28	Oncogene Science, Inc.	Detection and quantification of neu related proteins in the biological fluids of humans
CA2103059C (fr)	1991-06-14	2005-03-22	Paul J. Carter	Methode de production d'anticorps humanises
US6759217B2 (en) *	1996-03-26	2004-07-06	Oncomedx, Inc.	Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
KR20060079258A (ko)	1996-10-18	2006-07-05	제넨테크, 인크.	항-ＥｒｂＢ２ 항체
NZ516830A (en)	1999-06-25	2004-07-30	Genentech Inc	Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
US20040013667A1 (en)	1999-06-25	2004-01-22	Genentech, Inc.	Treatment with anti-ErbB2 antibodies
EP1488007A4 (fr)	2002-03-13	2006-05-03	Genomic Health Inc	Profilage d'expression genique dans des tissus tumoraux ponctionnes
US20040248151A1 (en)	2002-04-05	2004-12-09	Ventana Medical Systems, Inc.	Method for predicting the response to HER2-directed therapy
GB0215509D0 (en)	2002-07-04	2002-08-14	Novartis Ag	Marker genes
NZ537660A (en)	2002-07-15	2008-12-24	Genentech Inc	Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
ES2246191T1 (es) *	2002-12-11	2006-02-16	Ventana Medical Systems, Inc.	Metodo para predecir la respuesta a la terapia dirigida a her2.
JP2006521793A (ja)	2003-02-06	2006-09-28	ゲノミックヘルス，インコーポレイテッド	Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
BRPI0408950A (pt)	2003-04-01	2006-03-28	Monogram Biosciences Inc	método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica
NZ543234A (en)	2003-05-30	2009-04-30	Astrazeneca Uk Ltd	Marker genes and uses thereof to identify cancer patients that will respond to erbb tyrosine kinase inhibitors
WO2005011607A2 (fr)	2003-08-01	2005-02-10	Smithkline Beecham Corporation	Traitement des cancers exprimant p95erbb2
EP1682675A2 (fr)	2003-10-28	2006-07-26	Bayer HealthCare AG	Procedes et compositions de prediction de reponse de la neoplasie maligne a un traitement
TWM256978U (en) *	2004-04-02	2005-02-11	Nventec Appliances Corp	Electronic device
ZA200704796B (en) *	2004-12-07	2008-11-26	Genentech Inc	Selecting patients for therapy with a HER inhibitor
RU2300111C2 (ru) *	2005-06-15	2007-05-27	Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН)	Способ прогнозирования течения заболевания раком молочной железы

2006
- 2006-05-19 US US11/438,033 patent/US7700299B2/en not_active Expired - Fee Related
- 2006-05-23 TW TW095118273A patent/TW200741010A/zh unknown
- 2006-05-24 DK DK06743052.0T patent/DK1915460T3/da active
- 2006-05-24 PT PT06743052T patent/PT1915460E/pt unknown
- 2006-05-24 KR KR1020117011685A patent/KR20110074921A/ko not_active Ceased
- 2006-05-24 PL PL06743052T patent/PL1915460T3/pl unknown
- 2006-05-24 NZ NZ565270A patent/NZ565270A/en not_active IP Right Cessation
- 2006-05-24 AR ARP060102149A patent/AR057323A1/es not_active Application Discontinuation
- 2006-05-24 AT AT06743052T patent/ATE493514T1/de active
- 2006-05-24 EP EP06743052A patent/EP1915460B1/fr active Active
- 2006-05-24 WO PCT/EP2006/004950 patent/WO2007019899A2/fr not_active Ceased
- 2006-05-24 AU AU2006281746A patent/AU2006281746B2/en not_active Ceased
- 2006-05-24 DE DE602006019265T patent/DE602006019265D1/de active Active
- 2006-05-24 HR HR20110171T patent/HRP20110171T1/hr unknown
- 2006-05-24 EP EP10156100A patent/EP2196547B1/fr active Active
- 2006-05-24 CA CA002616913A patent/CA2616913A1/fr not_active Abandoned
- 2006-05-24 JP JP2008525399A patent/JP2009504142A/ja active Pending
- 2006-05-24 CN CNA2006800289513A patent/CN101405405A/zh not_active Withdrawn
- 2006-05-24 AT AT10156100T patent/ATE539171T1/de active
- 2006-05-24 UA UAA200803055A patent/UA93989C2/ru unknown
- 2006-05-24 BR BRPI0615001-2A patent/BRPI0615001A2/pt not_active IP Right Cessation
- 2006-05-24 RS RS20110132A patent/RS51859B/sr unknown
- 2006-05-24 KR KR1020087003440A patent/KR20080034922A/ko not_active Ceased
- 2006-05-24 SI SI200630946T patent/SI1915460T1/sl unknown
- 2006-05-24 CN CN200910204668A patent/CN101705287A/zh active Pending
- 2006-05-24 MX MX2008001926A patent/MX2008001926A/es active IP Right Grant
- 2006-05-24 ES ES06743052T patent/ES2356066T3/es active Active
- 2006-05-24 RU RU2008108907/10A patent/RU2408735C2/ru not_active IP Right Cessation
2008
- 2008-01-21 NO NO20080371A patent/NO20080371L/no not_active Application Discontinuation
- 2008-01-21 IL IL188923A patent/IL188923A0/en unknown
- 2008-01-24 CR CR9686A patent/CR9686A/es not_active Application Discontinuation
- 2008-02-06 MA MA30621A patent/MA31549B1/fr unknown
- 2008-02-11 EC EC2008008171A patent/ECSP088171A/es unknown
2009
- 2009-11-24 US US12/624,443 patent/US20100112603A1/en not_active Abandoned
2010
- 2010-04-19 RU RU2010115252/10A patent/RU2010115252A/ru not_active Application Discontinuation
- 2010-07-06 CL CL2010000720A patent/CL2010000720A1/es unknown
2011
- 2011-03-15 CY CY20111100286T patent/CY1111612T1/el unknown
- 2011-04-11 ZA ZA2011/02688A patent/ZA201102688B/en unknown
- 2011-05-19 AU AU2011202339A patent/AU2011202339A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE493514T1 (de)	2011-01-15
EP1915460B1 (fr)	2010-12-29
SI1915460T1 (sl)	2011-04-29
RU2408735C2 (ru)	2011-01-10
RU2008108907A (ru)	2009-09-20
WO2007019899A2 (fr)	2007-02-22
AU2006281746A1 (en)	2007-02-22
RS51859B (sr)	2012-02-29
WO2007019899A8 (fr)	2010-08-05
EP2196547B1 (fr)	2011-12-28
BRPI0615001A2 (pt)	2011-04-26
ES2356066T3 (es)	2011-04-04
US20100112603A1 (en)	2010-05-06
CR9686A (es)	2008-02-20
KR20080034922A (ko)	2008-04-22
HRP20110171T1 (hr)	2011-04-30
UA93989C2 (ru)	2011-03-25
DE602006019265D1 (de)	2011-02-10
AR057323A1 (es)	2007-11-28
CL2010000720A1 (es)	2010-12-03
PT1915460E (pt)	2011-03-17
MX2008001926A (es)	2008-03-24
ECSP088171A (es)	2008-03-26
WO2007019899A3 (fr)	2007-04-05
RU2010115252A (ru)	2011-10-27
CN101705287A (zh)	2010-05-12
CA2616913A1 (fr)	2007-02-22
JP2009504142A (ja)	2009-02-05
TW200741010A (en)	2007-11-01
ZA201102688B (en)	2012-01-25
US7700299B2 (en)	2010-04-20
US20070037228A1 (en)	2007-02-15
DK1915460T3 (da)	2011-01-31
ATE539171T1 (de)	2012-01-15
CY1111612T1 (el)	2015-10-07
KR20110074921A (ko)	2011-07-04
EP2196547A1 (fr)	2010-06-16
CN101405405A (zh)	2009-04-08
PL1915460T3 (pl)	2011-05-31
IL188923A0 (en)	2008-08-07
NZ565270A (en)	2011-05-27
EP1915460A2 (fr)	2008-04-30
AU2006281746B2 (en)	2011-06-23
AU2011202339A1 (en)	2011-06-09
MA31549B1 (fr)	2010-08-02

Publication	Publication Date	Title
NO20080371L (no)	2008-05-09	Fremgangsmate for a forutsi responsen overfor en behandling
WO2006063042A3 (fr)	2007-02-08	Selection de patients pour une therapie avec un inhibiteur de her
NO20074389L (no)	2007-12-06	Bestemmelse av respondere til kjemoterapi
NZ593225A (en)	2012-10-26	Gene expression markers (CMYC and Ki-67) for colorectal cancer prognosis
WO2008089994A8 (fr)	2009-05-22	Utilisation de igfbp-7 dans l'évaluation d'une insuffisance cardiaque
SE0301951D0 (sv)	2003-06-30	New method
EA201170933A1 (ru)	2012-02-28	Анализ нуклеиновых кислот, полученных из единичных клеток
NZ587750A (en)	2012-10-26	Molecular diagnosis and classification of malignant melanoma
ATE511656T1 (de)	2011-06-15	Verfahren zur risikobewertung von herzeingriffen auf gdf-15-basis
EP2115158A4 (fr)	2009-12-30	Traitement de donnees, et methode d'analyse de donnees d'expression de genes pour identifier les genes de reference endogenes
ATE539170T1 (de)	2012-01-15	Abschätzung und verringerung des risikos von graft-versus-host-reaktion
MX2019006565A (es)	2019-08-22	Medio de cultivo para celulas madre epiteliales y organoides que comprenden las celulas madre.
ATE427995T1 (de)	2009-04-15	Verbesserte methode zur transformation von sojabohnen
ATE541946T1 (de)	2012-02-15	Verfahren und system zur bestimmung von genkopiezahlvarianten
WO2008091814A3 (fr)	2009-03-12	Évaluation de l'asthme et d'une expression d'un gène dépendant d'un allergène
EP2232319B8 (fr)	2017-10-18	Procédé et système pour identifier des lames porte-échantillon biologique en utilisant des empreintes de lame unique
TW200636076A (en)	2006-10-16	Method for measuring resistance or sensitivity to docetaxel
WO2010127417A3 (fr)	2010-12-29	Carcinome hépatocellulaire
EP2006393A4 (fr)	2009-11-18	Procede d'analyse d'acides nucleiques
ATE414701T1 (de)	2008-12-15	Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
ATE459883T1 (de)	2010-03-15	Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
WO2008029290A3 (fr)	2008-07-17	Identification de cellules souches cancéreuses au moyen de marqueurs génétiques
WO2009132928A3 (fr)	2009-12-23	Marqueurs moléculaires pour le pronostic d'un cancer
WO2005069187A3 (fr)	2006-03-02	Procedes et systeme destines a l'identification et a la caracterisation de peptides et de leurs rapports fonctionnels, utilisant des mesures de correlation
ATE456797T1 (de)	2010-02-15	Verwendung von nogo-c bei der beurteilung von herzversagen

Legal Events

Date	Code	Title	Description
2012-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application